Oral Pharmacokinetics of Sulfasalazine, Paracetamol, Fexofenadine and Valsartan Using Different Administration Mediums

Inclusion Criteria: * ethnic origin: Caucasian * body mass index: ≥ 18.5 kg/m² and ≤ 30 kg/m² * good health as evidenced by the results of the clinical examination, ECG, and the laboratory check-up, which are judged by the clinical investigator not to differ in a clinical relevant way from the normal state * written informed consent Exclusion Criteria: * weight less than 45 kg * claustrophobia * tinnitus * cardiac pacemakers, metallic, plastic or silicone implants, dental retainer or metal-containing tattoos and piercings, Permanent Make-Ups, intrauterine devices * known allergic reactions/ hypersensitivity to the active ingredients used or to constituents of the study medication (e.g. lactose, lecithin, sulfonamides, salicylates) * bronchial asthma (all stages) and other known allergic diseases * existing cardiac, haematopoietic or hematological diseases and/or pathological findings, which might interfere with the drug's safety, tolerability and/or pharmacokinetics or the requirements for the magnetic resonance tomography * known hyperkalemia, hyponatremia or hypovolemia or medications that may cause these conditions. * Hepatic, renal or metabolic diseases and/or pathological findings, which might interfere with pharmacokinetics and pharmacodynamics of the study medication (e.g. liver failure, kidney failure, acute intermittent porphyria). * gastrointestinal diseases and/or pathological findings, which might interfere with gastrointestinal motility and emptying processes and interfering with pharmacokinetics and pharmacodynamics of the study medication (e.g. ileus) * Erythema exsudativum multiforme. * Glucose-6-phosphate dehydrogenase deficiency (G6PD deficiency). * Acute, chronic or recurrent infections. * drug or alcohol dependence * positive drug or alcohol screening * smokers of 10 or more cigarettes per day * positive results in HIV, hepatitis B virus and hepatitis C virus screenings * subjects who are on a diet which could affect gastrointestinal motility or the pharmacokinetics of the drug (vegetarian, vegan) * eating disorders e.g. anorexia, bulimia * heavy tea or coffee drinkers (more than 1l per day) * lactation and/or pregnancy test positive or not performed * subjects suspected or known not to follow instructions * subjects who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to as a result of their participation in the study * subjects liable to orthostatic dysregulation, fainting or blackouts * participation in a clinical trial during the last 3 months prior to the planned start of the study less than 3 months after last blood donation * therapy with transdermal patches * any systemically available medication within 2 weeks prior to the intended first administration unless because of the terminal elimination half-life complete elimination from the body can be assumed for the drug and/or its primary metabolites (except oral contraceptives) * intake of grapefruit or poppy seeds containing products within 14 days prior to the start of the study * Females who don't fulfil the criteria for contraception as listed in section 7.5.1 of this protocol